Quintrio
Home

PHARMACEUTICAL PREPARATIONS

PUMA BIOTECHNOLOGY INC

PBYI

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Last trade $7.01
Day change -$0.33 (-4.50%)
Day range $6.93 – $7.32
Volume 291,777
Market cap $379M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$379.47M
Price / earnings
15.92×
Price / book
2.59×
Price / sales
1.64×
EV / sales
1.46×
EV / EBITDA
9.3×

Profitability

Earnings per share
$0.46
Return on assets
11.75%
Return on equity
16.25%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.03×
Quick ratio
2.81×
Cash ratio
0.8×

Cash flow

Price / cash flow
8.24×
Price / free cash flow
8.25×
Free cash flow
$46M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PBYI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$55.06M$56.5M$44.81M$75.45M$54.48M$52.44M$46.01M$59.08M
Cost of revenue$15.2M$12.48M$10.42M$23.13M$12.17M$12.3M$10.56M$13.92M
Gross profit$39.86M$44.03M$34.39M$52.33M$42.3M$40.14M$35.45M$45.16M
Selling, general and administrative$16.3M$17.55M$18.42M$18.38M$16.82M$18.05M$17.6M$16.62M
Research and development$18.28M$18.9M$19.8M$16.84M$15.91M$15.45M$13.86M$15.17M
Total operating expenses$34.58M$36.44M$38.22M$35.22M$32.73M$33.5M$31.47M$31.79M
Operating income$5.27M$7.59M-$3.83M$17.11M$9.57M$6.64M$3.98M$13.37M
Interest expense$0-$180K-$731K-$1.12M-$1.49M-$1.84M-$2.18M-$2.62M
Income before taxes$6.17M$8.25M-$3.43M$17.11M$9.24M$6.17M$3.27M$12.24M
Income taxes$216K$56K$326K$3.67M$399K$310K$293K-$7.07M
Net income$5.96M$8.19M-$3.75M$13.44M$8.84M$5.86M$2.97M$19.31M
Net income attributable to common shareholders$5.96M$8.19M-$3.75M$13.44M$8.84M$5.86M$2.97M$19.31M
EBITDA$7.73M$10.1M-$1.24M$19.76M$12.3M$9.4M$6.78M$16.21M
Basic earnings per share$0.12$0.16-$0.07$0.27$0.18$0.12$0.06$0.39
Diluted earnings per share$0.11$0.16-$0.07$0.26$0.17$0.12$0.06$0.38

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Puma: 3 Key Takeaways for Long-Term Investors

Puma Biotechnology reported Q3 2026 revenue of $55.1 million with three key developments: the company became debt-free after paying off its final loan to Athyrium, generic competition in China reduced royalty revenue by $2.1 million prompting lower full-year guidance, and interim trial data for alisertib supports advancement to phase III breast cancer studies. With $108.5 million in cash and growing U.S. NERLYNX demand, Puma is balancing core product commercialization with clinical expansion while maintaining positive net income.

Zacks Investment Research

Puma Biotech (PBYI) Tops Q3 Earnings Estimates

Puma Biotech reported Q3 2026 earnings of $0.15 per share, beating consensus estimates of $0.11 by 36.36%, but revenues of $55.1 million missed expectations by 3.54%. The company has outperformed the market by 79.7% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates

Adma Biologics reported Q3 2026 earnings of $0.22 per share, beating consensus estimates of $0.19, with revenues of $141.1 million slightly exceeding expectations. However, the stock has declined 39.1% year-to-date versus the S&P 500's 10.6% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology

Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities. Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027.

Zacks Investment Research

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.